Senior Research Associate at Lyell Immunopharma

Seattle, Washington, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, Immunotherapy, OncologyIndustries

Requirements

BSc in Biology, Immunology, Biotechnology, Bioengineering, or related field with a minimum of 7 years’ experience within the area of focus; or MSc in Biology, Immunology, Biotechnology, Bioengineering or related field with a minimum of 5 years’ experience within the area of focus
Demonstrated experience with scale-up and optimization of bioreactors for cell-based therapies
Proven experience in GMP manufacturing setting, technology transfer (e.g., from academic institutions or to a third-party contract manufacturing organization (CMO)) and implementation of new technologies in a regulated environment (e.g., GMP, GLP, GxP)
Experience with the assessment of new technologies, preferably in a cross-functional setting where impact of new technologies is evaluated across research, development and commercial organizations
Demonstrated cell therapy experience
Experience with scale-down model implementation and process characterization
Understands the theoretical basis and experimental objectives and how they fit into the overall project and broader company goals; can give input based on literature knowledge to drive the direction of the project
Highly proficient in using Microsoft Office (Word, Excel, PowerPoint) and data analysis software packages (Prism, Flow Jo, Spotfire, Geneious, etc)
Effectively communicate, collaborate and discuss results with other scientists on the team
Ability to work effectively in a team environment as well as individually

Responsibilities

Execute experiments to optimize process and product quality parameters, enhance cell therapy engineering and manufacturing capacity, apply Quality by Design (QbD) principles and Design of Experiment (DoE) methodologies, where appropriate
Support cross-functional collaborations/projects with research, analytical and manufacturing stakeholders
Collaborate with internal and external partners to evaluate new process technologies to develop next generation processes
Work effectively in a team environment as well as contributing individually to meet project timelines and deliverables
Support authorship of technical reports, regulatory documents and summaries of experiments and investigations
Participate in authorship and review of batch records and SOPs
Assist in the execution of comparability packages supporting the implementation of process changes

Skills

CAR T-cell therapies

cell therapy engineering

process optimization

Quality by Design

QbD

Design of Experiment

DoE

T-cell biology

cell manufacturing

Lyell Immunopharma

Develops advanced cell therapies for cancer

About Lyell Immunopharma

Lyell Immunopharma develops advanced cell therapies aimed at treating solid tumors, which are cancerous tissue masses. The company focuses on enhancing T cells, a type of immune cell, to effectively target and eliminate cancer cells. Their approach includes genetic and epigenetic reprogramming of T cells to address challenges like T cell exhaustion and to ensure T cells can persist in the body. Unlike many competitors, Lyell is dedicated to creating curative treatments specifically for solid tumors, utilizing a diverse product pipeline that explores various treatment methods. The goal is to push the limits of current cancer therapies and provide effective solutions where traditional treatments have not succeeded.

San Francisco, CaliforniaHeadquarters

2018Year Founded

$479.6MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

201-500Employees

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

401(k) Company Match

Commuter Benefits

Phone/Internet Stipend

Risks

Increased competition in T-cell therapies may impact Lyell's market share.

Delays in clinical data results could lead to investor uncertainty.

Integration challenges from ImmPACT Bio acquisition may divert focus from core operations.

Differentiation

Lyell focuses on T cell reprogramming to treat solid tumors effectively.

Their proprietary Gen-R and Epi-R platforms address T cell exhaustion and stemness.

Lyell's diverse product pipeline explores multiple treatment modalities for solid tumors.

Upsides

Acquisition of ImmPACT Bio enhances Lyell's CAR T-cell therapy capabilities.

Strategic partnership with MaxCyte boosts cell engineering and therapeutic development.

New leadership appointments strengthen Lyell's strategic direction and management.

Land your dream remote job 3x faster with AI

Try Jobo Free